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ABSTRACT  
   
The majority of chronic myeloid leukemia (CML) and some of acute 
lymphocytic leukemia (ALL) cases are associated with possessing the 
BCR-Abl fusion protein from an oncogenic translocation, resulting in a 
constantly active form of Abl and rapid proliferation. CML and ALL cells 
that possess the BCR-Abl fusion protein are known as Philadelphia 
chromosome positive (Ph+). Currently, Imatinib (selective Abl inhibitor) is 
used as therapy against CML and ALL. However, some patients may have 
malignancies which show resistance to Imatinib.   
Previous work displays that the transformation of progenitor B cells 
with the v-Abl oncogene of Abelson murine leukemia virus results in cell 
cycle progression, rapid proliferation, and potentially malignant 
transformation while preventing any further differentiation. Progenitor B 
cells transformed with the temperature-sensitive form of the v-Abl 
oncogene have served as a model to study cellular response to Imatinib 
treatment. After some manipulation, very few cells were forced to progress 
to malignancy, forming tumor in vivo. These cells were no long sensitive to 
v-Abl inactivation, resembling the Imatinib resistant ALL.  
Autophagy is the process by which proteins and organelles are 
broken-down and recycled within the eukaryotic cell and has been 
hypothesized to play a part in cancer cell survival and drug-resistance. 
LC3 processing is a widely accepted marker of autophagy induction and 
progression. It has also been shown that Imatinib treatment of Ph+ 
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leukemia can induce autophagy. In this study, we examined the 
autophagy induction in response to v-Abl inactivation in a Ph+-B-ALL cell 
model that shows resistance to Imatinib. In particular, we wonder whether 
the tumor cell line resistant to v-Abl inactivation may acquire a high level 
of autophagy to become resistant to apoptosis induced by v-Abl 
inactivation, and thus become addicted to autophagy. 
 Indeed, this tumor cell line displays a high basal levels of LC3 I 
and II expression, regardless of v-Abl activity. We further demonstrated 
that inhibition of the autophagy pathway enhances the tumor line's 
sensitivity to Imatinib, resulting in cell cycle arrest and massive apoptosis. 
The combination of autophagy and Abl inhibitions may serve as an 
effective therapy for BCR-Abl positive CML. 
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Introduction 
 
CML, ALL, BCR, Abl 
 The majority of chronic myeloid leukemia (CML) and some cases of 
acute lymphoblastic leukemia (ALL) are two forms of cancer which 
originate from the same genetic modification of stem cells in the bone 
marrow1-5.  CML is distinguishable from ALL in that the cancer-causing 
modification occurs in myeloblasts, causing proliferation of mature and 
precursor granulocytes1.  In ALL, lymphoblasts acquire the genetic 
modification, which is typified by proliferating immature B cells1. 
 The genetic modification which gives rise to these two forms of 
cancer is an oncogenic translocation which yields a hybrid chromosome 
known as the Philadelphia chromosome.  The formation of the 
Philadelphia chromosome occurs when the q34 region of chromosome 9 
is substituted at the q11 region of chromosome 222-4.  Therefore, 
denotation for this translocation is t(9;22)(q34;q11).  Most importantly, this 
translocation juxtaposes the Abl (Abelson) gene from chromosome 9 with 
the BCR (breakpoint cluster region) gene from chromosome 22 (see 
Figure 1)2-4.   
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Figure 1.  Schematic of the oncogenic translocation which results in the 
Philadelphia chromosome.  
 Cells possessing the Philadelphia chromosome produce a fusion 
protein known as BCR-Abl.  Although the function of the normal BCR gene 
product is not clear6, the Abl gene product (c-Abl) has been shown to have 
a nuclear function and a cytoplasmic function as a tyrosine kinase5.  DNA 
damage causes translocation of cytoplasmic Abl to the nucleus, where it is 
activated and plays roles in cell cycle arrest and the induction of 
apoptosis3-5.  However, cytoplasmic Abl has a contrasting function in 
which it, upon phosphorylation, is a transducer of growth factor signaling 
which results in the positive regulation of cell proliferation, differentiation 
and adhesion1-6.  
 The BCR-Abl fusion protein localizes solely in the cytoplasm since 
the region of Abl containing the nuclear localization signal is replaced by 
the translocation.  Therefore, the DNA damage-repair and apoptosis 
inducing functions of BCR-Abl are ablated, resulting in genome 
instability7,11.  BCR-Abl’s oncogenic properties are expanded by the fact 
Chr 9
Chr 22
Abl gene at q34
BCR gene at q11 Philadelphia Chromosome
BCR‐Abl
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that it is constitutively active and does not require any extrinsic or intrinsic 
signals for activation8-10.  The result is enhanced cell proliferation, survival 
and tumor transformation2,5-7. 
 Currently, the first line of treatment for BCR-Abl positive CML and 
ALL is a selective Abl-inhibitor known as Imatinib (also known as Gleevec 
or STI571).  Imatinib acts as an antagonist for the kinase domain of BCR-
Abl, preventing its enzymatic function as an activator of pro-
proliferation/survival pathways12-16.  Imatinib-resistance is a major problem 
for patients with Philadelphia chromosome positive (Ph+) ALL in that 70% 
of patients develop resistance within 36 months of treatment17-19.  
Following the development of resistance, the disease state in these 
patients progresses rapidly and aggressively18.  Characterization of these 
tumors is essential for the development of therapy targeted to these 
aggressive cancers.     
 Abelson murine leukemia virus (Ab-MuLV) can transform many cell 
types in vitro through the production of the v-Abl protein20.  The C-Abl 
proto-oncoprotein is the normal cellular homolog to v-Abl.  V-Abl 
resembles BCR-Abl in that it is also constitutively active, does not 
participate in the induction of apoptosis or DNA damage-repair, and 
causes rapid cell proliferation5,20,21.  Given the similarities between BCR-
Abl and v-Abl, the Abelson leukemia virus has served as a useful tool in 
the understanding of oncogenic transformation and tumor induction in Ph+ 
malignancies.   
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 Interestingly, in vivo, in v-Abl transforms only partially differentiated 
B cells (pro- or pre-B cells) in which only the heavy chains have been 
rearranged21.  Oncogenic transformation of Pre-B cells by v-Abl is 
characterized by three phases: 1) an initial phase of proliferation, also 
known as primary transformation; 2) a crisis phase that is characterized by 
erratic growth patterns and massive apoptosis and; 3) the cells which 
survive the crisis phase acquire some alterations (explained later) which 
allow them exit crisis and emerge as fully transformed malignancies25,26.  
A temperature-sensitive form of Ab-MuLV (ts- Ab-MuLV ) has been 
developed via site-directed mutagenesis of Ab-MuLV using sequence 
information from temperature-sensitive mutants of a closely-related 
oncogene24, which allows delineation of mechanistic steps in oncogenic 
transformation as well as the sensitivity and responses of these cells to v-
Abl inactivation.    
 Infection of Pre-B cells with ts-Ab-MuLV produces an inducible 
model of v-Abl activity in that, at lower temperatures (33°), v-Abl is active 
and able to function as an oncoprotein while at higher temperatures (39°), 
v-Abl is inactivated.  By transforming progenitor B cells with the 
temperature-sensitive version of Ab-MuLV, an inducible model of ALL has 
been developed.   More specifically, holding these model cells at the v-
Abl-inactivating temperature mimics treatment of ALL with Imatinib, 
causing cell cycle arrest and differentiation22,23. 
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 In this study, the tumorigenic potential of v-Abl transformation was 
examined in pre-B cells harvested from severe combined immunodeficient 
(SCID) mice which also are defective in the catalytic subunit of the DNA-
damage-repair protein known as DNA-dependent protein kinase (DNA-
PKcs).  These SCID cells were then infected with ts-Ab-MuLV for 
transformation.  Additionally, these cells are being used, by other 
members of our group, as a model to study the role of defective 
recombination in oncogenic transformation.  To develop Imatinib-resistant 
cell lines from this model, the cells were subjected to the v-Abl-inactivating 
temperature for differing amounts of time, and then returned to the v-Abl-
permissible temperature.  Following v-Abl-inactivation, the parental cell 
line (called S9) remains in G1 arrest indefinitely, even after the 
reactivation of v-Abl.   
 However, a small number of cells were found to escape the G1 
arrest, return to the cell cycle and, therefore, progress to an Imatinib-
resistant-like state of malignancy.  Further testing of these new cell lines 
with Imatinib confirmed their resistance to terminal cell cycle arrest.  
These lines were also found to form tumor in vivo.  One of these malignant 
lines, called 3-4-1, will be the focus of this study.         
                             
Autophagy 
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 Autophagy is the process by which proteins and organelles are 
broken-down and recycled within the eukaryotic cell.  This can occur in a 
nutritionally-insufficient environment as a means of creating metabolic 
substrates from within, or when long-lived proteins or organelles are 
damaged or redundant as a means of removal27.  All in all, the overall goal 
of autophagy is hypothesized to be the maintenance of cellular 
homeostasis.  Insufficient autophagic degradation of proteins may lead to 
cell death27,28.  However, abnormal autophagy has also been 
hypothesized to play a part in oncogenesis, cancer cell survival and drug-
resistance27-29. 
 Autophagy involves the selective degradation of proteins via 
lysosomes in two different ways30,31.  In chaperone-mediated autophagy, 
proteins that are coupled with a lysosomal-targeting region are removed 
from the cytoplasm when they are recognized by a specific chaperone and 
shuttled to lysosomes for internalization and degradation30,31.  The second 
form of autophagy is known as macroautophagy (to be referred to as 
autophagy for the remainder of this study) involves the encasement of the 
protein to be degraded by a double-membrane (isolation vesicle) vesicle 
known as an autophagosome27-31.   
 Once the autophagosome fully encloses the protein target, it fuses 
with a lysosome, making the internal autophagosomal environment acidic 
to the point of degrading all contents27-31.  Then these degraded contents 
are released to the cytoplasm for use in cellular metabolism27-31.  As 
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research ensues, more and more players on the autophagy pathway are 
being uncovered and characterized.  Some essential steps and 
components of this pathway have been previously described and following 
is an explanation of various processes (see Figure 2).     
 
Figure 2.  Diagram of the events that occur in the autophagic degradation 
of long-lived proteins in the cytoplasm. 
 The initiation of autophagy relies on the complex consisting of 
hVps34 (the PI3 kinase, more on PI3K later) with Beclin-1 (also known as 
Atg [autophagy-related gene] 6).  In order for this complex to form, Beclin-
1 must be released from its inhibitory complex with Bcl-2 upon Bcl-2 
activation32-35.  After binding with Beclin-1, hVps34 modifies lipids from the 
endoplasmic reticulum (ER) to form PtdIns(3)P (phosphatidylinositol 3-
phosphate) 34,35.  These lipids are essential for the lipidation (via 
conjugation to PE [phosphatidylethanolamine]) of LC3-I (microtubule-
associated light chain 3) into its further-lipidated form, LC3-II, which can 
Beclin 1
hVps34
+
PE LC3‐I
Phagophore 
with LC3‐II
+
Protein 
Target
+
PE LC3‐I
+
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then associate with the growing autophagosome34,35.  The association of 
LC3-II to the growing autophagosome is essential to the progression of 
autophagy34,35.   
 The premature (open) autophagosome is known as a phagophore 
and its nucleation site is known as the phagophore assembly site (PAS) 27-
36.  The growing phagophore recruits LC3-II on the inner concave and 
outer convex membrane as it grows and is thought to play a role in the 
shaping of the double membrane into a vesicle.  Once the 
autophagosome is fully formed and closed, it fuses with a lysosome and 
degrades the protein target within as well as the LC3-II that was 
associated with the inner membrane.  The LC3-II that was associated with 
the outer membrane is deconjugated from PE, transforming it back into 
LC3-I so it can be reused in the formation of another autophagosome27-36.  
Deconjugation of PE from LC3-II is carried out by ATG436. 
      LC3 processing is a widely accepted marker of autophagy 
induction and progression37-40.  This can be accomplished with anti-LC3 
antibodies and observation of the relative levels of LC3-I and –II as 
autophagy progresses.  Autophagy is not considered complete until the 
autophagosome has fused with a lysosome and the outer-membrane-
associated LC3-II is converted back to LC3-I.   
 Upregulation of the autophagy pathway can render cells resistant to 
apoptosis in a nutritionally insufficient or DNA-damaging environment or in 
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response to other stressors.  This is indicative by studies in which tumor 
cells induce autophagy in the presence of chemotherapies or radiation 
therapies41-46.  Interestingly, it has been shown that Imatinib treatment of 
BCR-Abl+ leukemia can induce autophagy47-49.  Inferred from this finding, 
we speculate that 3-4-1 cells, which show resistance to v-Abl inactivation, 
somehow may exploit autophagy as a means of surviving Abl-inhibition. 
 The emerging implications of the autophagy pathway in cancer cell 
metabolism and survival has prompted an explosion of investigations to 
unravel autophagy induction and modulation.  As the body of knowledge 
regarding autophagy grows, it has become evident that many cellular 
pathways are involved in the modulation of autophagy.  Currently, the 
major pathways to note are AMPK, mTOR, p53 and PI3K.   Although the 
complex interplay and balance between these pathways and autophagy is 
still not entirely understood, the key points regarding their links to v-Abl 
transformation and known control over autophagy will be explained below.   
 
AMPK, mTORC1, p53 and PI3K Pathways 
 The AMP-activated protein kinase (AMPK) pathway is stimulated by 
elevated AMP:ATP ratios, acting as a sensor for low glucose levels and 
metabolic stress50.   Activated AMPK enhances the oxidation of fatty acids 
and glucose metabolism while preventing the synthesis of fatty acids, 
proteins, cholesterol and glycogen (see Figure 3).  Activation of AMPK, 
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required for kinase activity, depends upon phosphorylation at T172 by 
AMP51.  AMP not only promotes phosphorylation of AMPK at T172, but 
also has the ability to stabilize this phosphorylated state52.  High 
concentrations of ATP have been shown to prevent AMPK activity by 
competitively binding to the enzyme’s active site, preventing downstream 
pathway progression53.    
 
 
 
Figure 3.  Role of AMPK as a cellular-energy-sensor. 
 Harhaji-Trajovic et al. have shown that AMPK-activation occurred 
just prior to induction of autophagy in cisplatin-treated cells, which results 
in reduction of p70S6 kinase phosphorylation by mammalian target of 
Rapamycin (mTOR)54.  The mTOR protein, in combination with Raptor 
and GβL, form a complex known as mTOR complex 1 (mTORC1)55-57.  
The active mTOR complex can phosphorylate and activate S6 kinase 
(also known as p70S6K) which, in turn, can positively regulate ribosomal 
biogenesis and cell growth as well as inhibit autophagy57.  
AMPK
ATP
AMP
AMP:ATP
Balance
Fatty Acid Oxidation
Glucose Uptake
Synthesis of:
Proteins, Glycogen,
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 AKT (also known as PKB [protein kinase B]), is phosphorylated and 
activated by PIP3 (product of PI3K class-I function, described below).  
AKT has been shown to play roles in metabolism, proliferation and 
survival.  Furthermore, activation of mTOR relies on AKT to phosphorylate 
the mTOR-inhibitor known as TSC2 (tuberous slcerosis complex 2), which 
removes its suppressive actions on mTOR69,70.  All in all, expression of v-
Abl leads to proliferation by enhancing PI3K activation, leading to AKT 
activation and, therefore, reduction of p53 activation (see figure 6). 
 Research to elucidate the interactions among AMPK, mTOR and 
autophagy have further uncovered that nutrient-deprivation-mediated 
activation of AMPK inhibits mTORC1 which, in turn, inhibits cell growth 
and allows for the induction of autophagy until adequate growth factors 
are restored (see Figure 4)57.  Furthermore, AMPK-silencing (via siRNA) 
prevented the induction of drug-induced autophagy54 and silencing of 
mTOR (via siRNA) alone lead to autophagy initiation54.       
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Figure 4.  Interactions between AMPK and mTOR and their role in 
induction of autophagy.  
 One of the common denominators that have been shown to 
regulate both the AMPK and mTOR pathways is p53.  P53 is a nuclear 
tumor suppressor protein that plays a positively-regulatory role in multiple 
pathways such as senescence, cell death and autophagy.  P53 has been 
found to be mutated in the majority of cancers and its oncogenic effects 
have been notoriously explored58-65.  Upon phosphorylation, p53 can leave 
the nucleus and act in the cytoplasm on the mentioned pathways in an 
indirectly-activating manner as described below.     
 Tasmedir et al has shown that p53 can have dual functionality in 
the activation of autophagy which may be dependent on the initial cause 
of its phosphorylation (i.e. oxidative stress, DNA damage, nutrient-
deprivation etc.)63.  In some cases, activated p53 has been shown to 
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P
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induce autophagy by activating AMPK which, in turn, inhibits mTORC1.  
The inhibition of mTOR leads to a reduction of phosphorylated S6K which 
will allow for autophagy to ensue.  Conversely, cytoplasmic-
phosphorylated-p53 has also been shown to inhibit the induction of 
autophagy as demonstrated by this group’s experiments in p53-null mice 
in which p53 degradation prompted by ubiquitination somehow allowed 
autophagy to proceed (see Figure 5).   
 They hypothesize that p53 may act as an endogenous repressor of 
autophagy in some cases and an inducer of autophagy in others.  It can 
be imagined that one path may be cytoprotective while the other might 
lead to apoptosis, depending on the stimulus which prompts the induction 
of inhibition of autophagy.  However, there is no general consensus 
describing this dichotomy and the factors which contribute to the cell’s 
decision to adopt one of these two paths remain to be discovered.    
 
  14 
 
 
Figure 5.  Schematic of the dual roles that p53 can play in the modulation 
of autophagy. 
 It is important to note the INK4A/ARF (CDKN2A) locus and its links 
to v-Abl transformation through interplay with the p53 pathway.  P19ARF 
(ARF) is one of the products of the CDKN2A gene and acts as a tumor 
suppressor by enhancing p53 activity, through the inhibition of p53’s 
inhibitor (MDM2), in the presence of oncogenic stress as a means of 
inducing cell cycle arrest or apoptosis in cells that have accumulated 
damage98.  Furthermore, malignant transformation by v-Abl is either 
accompanied by reduced expression of ARF, or an inactivating mutation in 
p53 as a means of overcoming the crisis phase (v-Abl transformation 
phase 2; described earlier) induced by oncogene expression99,100.  An in-
tact p53 pathway or increased expression of ARF was shown to prevent 
nucleus
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complete transformation by v-Abl through induction of cell cycle arrest and 
apoptosis99,100.  Additionally, ARF has been indicated to positively regulate 
autophagy75-77.      
 This additional potential role of p53 adds a new level of convolution 
to the motives of p53 in a v-Abl-transformed cell.  Activated/cytoplasmic 
p53 can act as a tumor suppressor by inducing autophagy and inhibiting 
cell cycle progression (via inhibition of the mTOR pathway).  Conversely, 
Tasmedir et al describe that activated p53 can inhibit autophagy by 
unknown means in cells that commit to this connection between p53 and 
autophagy.  In this case, activation of p53 must be reduced or p53 must 
be mutated or degraded in order for autophagy to ensue.      
 An additional pathway that was shown to be entangled in this 
AMPK-mTOR-p53-autophagy web is the PI3K pathway.  The PI3K 
(phosphatidylinositol 3-kinase) family of enzymes adds phosphate groups 
to phosphatidylinositol compounds.  They are separated into classes 
depending upon their substrates and stimuli to perform their kinase 
activities.  At the cell membrane, receptor-binding to growth factors (such 
as insulin or IGF-1) activate PI3K class-IA to convert membrane-bound 
PIP2 (phosphatidylinositol-4,5-phosphate) into PIP3 (phosphatidylinositol-
3,4,5-phosphate) which can leave the membrane.  Additionally, BCR-Abl 
transformation has been shown to increase PI3K-IA activity, leading to 
accumulation of PIP3 at the membrane93-97.  PIP3 is then able to recruit 
and activate AKT (see Figure 6)66-68.   
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 The PI3K pathway has a direct role in autophagy which is through 
the actions of a class-III PI3K known as Vps34 (vacuolar protein sorting 
34).  Vps34 functions as a PI3-kinase by processing PtdIns(3)P 
(phosphatidylinositol 3-phosphate) from lipids supplied by the ER 
(endoplasmic reticulum) which must be present for the induction of 
autophagy (Figure 2).  Vps34 is also essential for the conjugation of PE 
(phosphatidylethanolamine) to LC3-I, converting it to LC3-II so that it may 
associate to and facilitate the growing autophagosome.  It has also been 
shown that universal-PI3K-inhibiting drugs can inhibit autophagic 
processing66-68 and synergize with Imatinib in the treatment of Ph+ 
leukemias44. 
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Figure 6.  V-Abl/PI3K activity and its effects on autophagy via the mTOR 
pathway. 
 The enlightening findings on autophagy of many research groups in 
last decade have shown that many diseases (such as cancer, 
neurodegenration, cardiac disease and diabetes) may possess an altered 
autophagic process and use this alteration for cytoprotection in the 
presence of therapies71-74.  Given that 3-4-1 cells have been perturbed to 
acquire Imatinib-resistance, it is reasonable to wonder whether an altered 
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v-Abl/PI3K pathway and, therefore, an altered autophagy pathway, is one 
of the mechanisms by which these cells survive drug-treatment.   
 As previously mentioned, Imatinib has been found to induce 
autophagy: since Imatinib inhibits v-Abl, the PI3K pathway is down 
regulated which reduces the activation of AKT, which then inhibits the 
mTOR pathway, leading to induction of autophagy (see Figure 6).  Cancer 
cell survival in the absence of v-Abl activity (either by Imatinib treatment or 
v-Abl inactivation via temperature shift) could be achieved through 
compensation in the PI3K, AKT or autophagy pathways.  Given the 
potential link between the malignancy of 3-4-1 and autophagy, this study 
will explore various players in the autophagy pathway, as well as PI3K and 
AKT, and their modulation in the presence and removal of Imatinib.  We 
hypothesize that 3-4-1 may possess an altered autophagy pathway and 
exploits this abnormality to enhance drug-resistance and perpetuate its 
survival.   
 
Methods 
 
Cell Culture and ts-Ab-MuLV 
 S9 and 3-4-1 cells were cultured in medium consisting of RPMI 
1640 with 10% fetal bovine serum, 1mM L-glutamine, 100 U/ml 
streptomycin, 100ug/ml penicillin and 50 uM β–mercaptoethanol.  Cells 
were maintained at the v-Abl-permissible temperature (33°C) in a 5%CO2, 
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air-humidified incubator.  V-Abl was inactivated by holding cells at the v-
Abl-inactivating temperature (39°C) for 48 hours.  V-Abl reactivation was 
accomplished by returning cells to 33°C for 24 hours.   
Drug Treatments 
 All stock drugs were prepared in DMSO.  Final DMSO 
concentration in drug treated samples and control samples were 0.1%.  
AMPK-inhibitor (Compound C) and pan-PI3K-inhibitor (LY294002) were 
both obtained from CalBiochem/EMD Biosciences and applied to cells at a 
concentration of 10 uM for 24 hours at 33°C.  Imatinib (STI571) was 
purchased from LC laboratories and applied to cells at a concentration of 
1 uM for 48 hours at 33°C for inhibition of Abl.  Re-activation of Abl in 
Imatinib-treated cells was accomplished by removing the drug-containing 
media, washing in PBS, and re-plating in Imatinib-free media for an 
additional 48 hours at 33°C.  Doxorubicin was purchased from Sigma-
Aldrich and applied to cells at 40 ng/ml for 24 hours at 33°C to serve as an 
apoptosis control for western blot analysis.   
Cell Cycle, ROS, Doubling, and Apoptosis Analyses 
 Cells for cell cycle analysis were porated and stained in a solution 
containing 50 ug/ml propidium iodide, 1 mg/ml RNAse A, 0.1% Triton-X 
and 0.62% sodium citrate.  Stained cells were subjected to flow cytometry 
on a FACSCalibur (BD) and fluorescence intensity was analyzed with an 
FL2-A histogram using Cell Quest Pro software (also BD).   
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 ROS was measured by staining cells with the fluorescent dye 
DCFDA (dichlorofluorescein diacetate, from Sigma-Aldrich) at 2.5 uM per 
106 cells, according to the manufacturer’s protocol.  Stained cells were 
subjected to flow cytometry on a FACSCalibur (BD) and fluorescence 
intensity was analyzed with an FL1-H histogram using Cell Quest Pro 
software (also BD). 
 Doubling was assessed using a vital dye known as CFSE 
(carboxyfluorescein succinimidyl ester, from Invitrogen) at a final working 
concentration of 2 uM per 106 cells, according to the manufacturer’s 
protocol.  Stained cells were subjected to flow cytometry on a 
FACSCalibur (BD) and fluorescence intensity was analyzed with an FL1-H 
histogram using Cell Quest Pro software (also BD). 
 Apoptosis analysis was accomplished by double-staining cells with 
50 ug/ml propidium iodide (red fluorescence) and 50 uM FITC-conjugated 
Annexin-V protein (green fluorescence) per 106 cells.  Stained cells were 
subjected to flow cytometry on a FACSCalibur (BD) and red vs. green 
positive fluorescent staining was analyzed with an FL1-H vs. FL2-A dot 
plot using Cell Quest Pro software (also BD).   
Western Blot Detection of Various Proteins  
 The cells were lysed in RIPA buffer supplemented with 2% Triton-X 
as suggested by Tanida et al (2008) and Kimura et al (2009).  Additionally, 
washed cells were suspended in lysis buffer and passed through a 20 
gauge syringe 20 times, and then incubated on ice for 30 minutes to 
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complete lysis.  The lysates were not centrifuged to maintain the 
membrane fraction in the lysate suspension and, therefore, all of the 
membrane-associated proteins (i.e. LC3-II).   
 Equal amounts of protein from each sample was separated by 
SDS-PAGE and transferred on ice to PVDF membrane.  Membranes were 
incubated with their respective primary antibodies overnight at 4°C.  
PARP, caspase-3, phosphorylated-p53, p21, phosphorylated-AKT, and 
AKT antibodies were purchased from Cell Signaling.  XIAP antibody was 
purchased from Abcam.  LC3, GAPDH, Atg4, and p19ARF antibodies 
were purchased from Sigma-Aldrich.  Actin antibody was purchased from 
Santa Cruz Biotechnology.  The Membranes were then incubated in the 
appropriate peroxidase-conjugated secondary antibody (either goat-anti-
rabbit or goat-anti-mouse, both from BioRad) for one hour at room 
temperature.  Specific bands corresponding to each protein assessed was 
detected using enhanced chemiluminescence reagents (Pierce brand 
carried by Thermo Scientific).  Luminescent signal was transferred to 
autoradiography film (Santa Cruz Biotechnology) and developed.      
Electron Microscopy 
 S9 and 3-4-1 cells were incubated at 39°C for 48 hours to inactivate 
v-Abl, then returned to 33°C for 72 hours to re-activate v-Abl.  These cells 
were then fixed and imaged using transmission electron microscopy at the 
Life Sciences EM Facility at Arizona State University.  The transmission 
electron microscope was a Philips CM12, operated at 80 kV.  Images 
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were captured with a Gatan model 791 camera, and analysis of images 
was accomplished with Gatan Digital Micrograph software version 3.9.1. 
 
Results 
 
3-4-1 is Imatinib-Resistant (Panels A and A-2) 
 The experiments in Panel A were to determine S9 and 3-4-1 cell 
responses to the inactivation and reactivation of v-Abl using the 
temperature-sensitive feature of ts-Ab-MuLV.  We analyzed their cell cycle 
profile and doubling relative to the parental cell line (S9) while using 
temperature to inactivate and re-activate v-Abl.  At 33°C, v-Abl is active 
and cells remaining at this temperature are the control cells.  Treatment 
with Imatinib is mimicked by shifting the cells to 39°C, at which v-Abl is 
inactivated, for 48 hours.  Then, to assess the effects of v-Abl reactivation, 
the cells were shifted back to the v-Abl-permissive temperature (33°C) for 
24 hours.  
 Cell Cycle.  The cell cycle profiles of all samples were determined 
via permeabilization and propidium iodide staining and subsequent flow 
cytometric analysis.  Propidium iodide directly stains DNA and, therefore, 
can indicate DNA content at different wavelengths.  This data can then be 
interpreted to the accumulation of DNA during the different phases of the 
cell cycle.  The M1 region of the histogram represents the apoptotic 
population of the sample, M2 represents cells in G0/G1, M3 represents 
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cells in S phase, M4 represents cells in the G2/M transition, and M5 shows 
aneuploidy.  S9 cells show G1 arrest upon v-Abl inactivation.  This G1 
arrest is maintained, even after v-Abl reactivation.  However, 3-4-1 cells 
show a slight G1 arrest when v-Abl is inactivated, followed by a robust re-
entry into the cell cycle upon v-Abl reactivation.  3-4-1’s ability to re-enter 
the cell cycle immediately following v-Abl inactivation is a clear sign of 
Imatinib-resistance. 
 Doubling.  The rate of cell doubling was assessed using a vital dye 
known as CFSE (carboxyfluorescein succinimidyl ester) which 
incorporates into the cell membrane and, therefore, is diluted with every 
cell division. Fluorescent intensity was measured via flow cytometry.  As 
cells divide/double, the fluorescent intensity of the histogram peak will shift 
to the left (lower fluorescent intensity).  The samples from cells in which v-
Abl was inactivated and reactivated (purple peaks) was overlaid with the 
peak acquired from the control cells for comparison.   S9 cells showed a 
reduction in doubling in both v-Abl inactivated and reactivated samples in 
comparison to the control rate of doubling.  3-4-1 cells show less doubling 
upon v-Abl inactivation.  When v-Abl was reactivated, 3-4-1 cells doubled 
faster than control cells.  These results correlate with their respective cell 
cycle profiles. 
 Imatinib Treatment.  The experiments in Panel A-2 were to 
establish if 3-4-1 cells are indeed resistant to Imatinib, S9 and 3-4-1 cells 
were treated with 0.1 uM of Imatinib, in 0.1% DMSO as a carrier, for 48 
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hours to inhibit v-Abl.  V-Abl reactivation was accomplished by washing 
the Imatinib-treated cells in PBS, then replacing the cells into Imatinib-free 
media for 48 more hours.  Then, these samples were analyzed for cell 
cycle through PI-staining followed by flow cytometry.  The data obtained 
for each phase of the cell cycle was normalized against the control 
(DMSO only) cells and represented in the histogram as percentages of the 
control, so the 100% mark of each bar is also the control (untreated) for 
that sample.    
 S9 and 3-4-1 cells both show G1 arrest when treated with Imatinib 
(first 2 blue bars).  Furthermore, much of the G1 arrest in both cell lines 
remains after Imatinib is removed (first 2 red bars).  Imatinib treatment 
dramatically reduces S phase in both cell lines (middle 2 blue bars).  
Removal of Imatinib allows the S phase in both cell lines to recover in a 
similar fashion (middle 2 red bars).  The G2 phase of the cell cycle is 
where the two cell lines differ dramatically.  Treatment of Imatinib reduces 
the G2 populations in both cell types (last 2 blue bars).  However, when 
Imatinib is removed (last 2 red bars), the G2 population of S9 cells 
remains relatively unchanged where as the G2 population of 3-4-1 cells is 
restored to over 125% of the control cells.   
 This data parallels the findings shown in Panel A, which indicate 
that 3-4-1 cells are able to robustly re-enter the cell cycle following 
attenuated growth-inhibition by v-Abl inactivation (either by temperature 
inactivation or chemical-inhibition via Imatinib).  Given that the 3-4-1 cell 
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cycle shows some arrest in the presence of Imatinib, it is important to note 
that this cell line is only somewhat resistant to Imatinib in that the cell 
cycle does not progress until Imatinib is removed from the cells.  However, 
v-Abl reactivation allows for 3-4-1 to robustly re-enter the cell cycle as 
seen in Panels A and A-2.  In Panel A-2, the G2 population after Imatinib-
removal (last 2 red bars) show that S9 cells maintain a similarly low 
number of cells as during Imatinib treatment.  However, the 3-4-1 cells a 
dramatic increase in G2 population after Imatinib-removal (red bar furthest 
to the right).  This increase in G2 population is indicative of cell cycle re-
entry.         
 
 
Panel A and A-2: 3-4-1 is Imatinib-resistant.  A: Left column is basal v-
Abl activity, middle column is inactive v-Abl and right column is re-
activated v-Abl.  Top half of panel is S9 cells and bottom half of panel is 3-
4-1 cells.  Each cell type has been subjected to 2 assays: 1) cell cycle 
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analysis via propidium iodide staining and 2) doubling assay via CFSE 
staining.  A-2: S9 and 3-4-1 cells were treated with 1uM Imatinib for 48 
hours (blue bars), followed 
by washing cells and 
replacement of Imatinib-
free media for 48 hours 
(red bars).  Cell cycle 
analysis (showing only G1, 
S and G2 phases) via PI-staining and data is normalized as a percent of 
control (untreated/DMSO only) cells. 
 
3-4-1 Has an Altered Autophagy Pathway (Panels B and C) 
 Immunoblotting and primary antibodies specific to various players 
in the autophagy pathway were used to determine autophagy progression 
and relative levels of autophagy-related-protein expression in S9 and 3-4-
1 cell lines at 4 conditions: 1) control cells constantly maintained at the v-
Abl-permissive temperature (+); 2) Cells that were held at the v-Abl 
inactivating temperature for 48 hours (-); 3) cells that were held at the v-
Abl-inactivating temperature for 48 hours, then returned to the v-Abl-
permissive temperature for 24 hours (++); and 4) cells that were treated 
with 40 ng/ml of Doxorubicin for 24 hours (DOX).  Doxorubicin is a DNA-
damaging agent to which both cell lines show sensitivity in the form of cell 
cycle arrest and partial apoptosis.  Doxorubicin-treated cells were included 
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to serve as a DNA-damage/apoptosis control.  Cell lysates were prepared 
as described by Tanida et al (2008) in order to maximize autophagy 
proteins that may be associated with the autophagosomes in the 
cytoplasm. 
3-4-1 shows elevated expression of autophagy-enhancing proteins (Panel 
B).   
 LC3-I/II turnover is a notorious marker for autophagy progression.  
Both cell lines show dramatically different levels of autophagy as indicated 
by the presence of LC3-I and –II at the different levels of v-Abl activity.  As 
seen in Figure 2, autophagy is a cyclic phenomenon in which LC3-I is 
converted to LC3-II as the autophagosome grows but, following lysosomal 
degradation of the protein target, LC3-II is recycled back to LC3-I for re-
use in the formation of another autophagosome.   
 In S9 cells, LC3 turnover from LC3-I to –II can be seen as v-Abl 
goes from a basally active state to inactivation.  When v-Abl is active, S9 
cells have some LC3-I and little, if any, LC3-II, meaning that these cells 
have a low level of basal autophagy and, therefore, a low level of LC3 
conversion.  Therefore, an active autophagy pathway can be shown by 
LC3-I and –II levels in which LC3-II indicates autophagosome formation, 
but LC3-I indicates the readiness to form autophagosomes and the 
continuation of the autophagy cycle following target protein degradation.   
 When v-Abl is inactivated, S9 cells accumulate LC3-II, but have 
little to no detectable LC3-I, meaning that the recycling of LC3-II to –I is 
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inhibited and, therefore, the autophagy pathway is not permitted to 
continue as a cycle.  The conversion of LC3-I to –II is expected upon v-Abl 
inactivation and cell cycle arrest, as the autophagy pathway should be 
inhibited in this situation (see Figure 6).    
 When v-Abl is reactivated in S9 cells, the effects of prolonged cell 
cycle arrest reduced levels of both LC3-I and –II to equally low levels, 
suggesting a correlation that the autophagy pathway is inhibited as long 
as cell cycle progression is inhibited.  A possible explanation for this 
reduction on both forms of LC3 could be that the LC3-I precursor was 
consumed during the autophagosome formation during v-Abl inactivation 
and was converted to LC3-II.  The inability of S9 to replenish LC3-I levels, 
when v-Abl is inactive or reactivated, could indicate that LC3 recycling is 
inhibited or that the synthesis of LC3 precursors is at a low level in S9.        
 However, 3-4-1 cells have high levels of both LC3-I and –II, which 
is a marker for high autophagic processing.  Interestingly, the increased 
level of both LC3I and II appeared not to be influenced by v-Abl activation 
status, indicating an enhanced autophagy level.  The lack of visible 
processing of LC3-I, to –II, and recycling could mean that 3-4-1 fails to up 
regulate autophagy according to v-Abl activation.  However, the high 
levels of both LC3 forms make it difficult to discern LC3 conversion, if any.  
When taking into consideration that v-Abl inactivation/Imatinib-treatment is 
able to somewhat inhibit cell cycle progression in 3-4-1 cells (Panels A 
and A-2), this LC3 data suggests that 3-4-1 cells have a high level of 
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autophagy, regardless of cell cycle progression.  However, since we did 
not explore any possible direct relationship between cell cycle and 
autophagy, this correlation remains speculation.  This may suggest that 3-
4-1 cells have been selected for high levels of autophagy in the presence 
of v-Abl inactivation. 
 As previously mentioned, the ATG4 protein acts in autophagy by 
converting LC3-II back to LC3-I at the conclusion of autophagy.  Increased 
ATG4 protein levels can indicate an increased autophagy pathway.  
Interestingly, expression of ATG4 in 3-4-1 was abolished when v-Abl was 
inactivated and remained at undetectable levels, even upon reactivation.  
All the while, S9 maintained a constant level of ATG4 expression.  
 Although this seems contradictory to all of the previously mentioned 
results, Rzymski et al (2010) identified ATG4 as a target of oxidative 
degradation by cellular ROS36.  As to be shown in Panel G, 3-4-1 cells 
have an elevated accumulation of ROS upon v-Abl inactivation, which is 
somewhat maintained when v-Abl is reactivated.  Given the correlation 
between the elevated ROS and reduction of ATG4 in 3-4-1 when v-Abl is 
inactivated, the potential for ATG4 to be degraded by ROS in these cells 
was of interest.    
 To further investigate this possibility in 3-4-1 cells, we repeated this 
experiment with the addition of NAC (N-acetylcysteine, Sigma-Aldrich).  
NAC is an antioxidant which can reduce free radicals such as ROS.  
However, the addition of NAC did not increase the amount of ATG4 
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visualized by Immunoblot (data not shown).  This suggests that the lack of 
ATG4 in 3-4-1 cells is not a result of oxidative degradation but, rather, is 
the result of some other cause.  
 Conversely, the lack of ATG4 in 3-4-1 cells may indicate incomplete 
autophagy.  This would also mean that 3-4-1 cells might have an 
accumulation of damaged/redundant proteins and/or 
organelles/mitochondria.  Therefore, the lack of ATG4 may be the cause 
of the elevated ROS seen in 3-4-1 as a result of erroneous protein 
accumulation.     
3-4-1 shows reduced expression of autophagy-inhibiting proteins (Panel 
C). 
 P19ARF (p19 alternate reading frame, also referred to as ARF) and 
smARF (small mitochondrial ARF) have been indicated to positively 
regulate autophagy75-77.  ARF is a tumor suppressor and the locus from 
which it originates is mutated in 40% of human cancers75.  The normal 
function of ARF is known to activate p53 by inhibiting its inhibitor Mdm2, 
which leads to cell cycle arrest and apoptosis76.  The shorter form of ARF, 
smARF, lacks the Mdm2-binding domain and, therefore, does not lead to 
p53 activation.  This shorter form of ARF is a product of translation from 
an internal methionine in the ARF transcript76.   Rather, smARF is known 
localize to the mitochondria, lowering mitochondrial membrane potential 
and potentially affecting the integrity and function of mitochondria77.  In 
addition, smARF is usually expressed proportionally to ARF and has been 
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shown to induce massive autophagy to the extent of leading to caspase-
independent cell death76.   
 Panel C contains western blot data representative of ARF and 
smARF protein levels in S9 and 3-4-1 cell in response to v-Abl activity.  In 
S9 cells, ARF and smARF are not expressed until v-Abl reactivation.  
However, in 3-4-1 cells, high levels of ARF and smARF are expressed at 
all conditions of v-Abl activity.  As previously mentioned, smARF and ARF 
can positively regulate autophagy while ARF can also activate p53 
(leading to cell cycle arrest or apoptosis).  The high levels of ARF and 
smARF expression in 3-4-1 cells correlate with the signs of an increased 
autophagy pathway (implicated by LC3-I and –II expression in Panel B).  
Additionally, enhanced ARF can lead to p53 activation and, ultimately, cell 
cycle arrest and apoptosis.   
 Although the cell cycle analyses of 3-4-1 cells showed limited cell 
cycle arrest upon v-Abl inactivation (by both holding at the inactivating 
temperature and treatment with Imatinib), ARF and smARF levels seem 
unaffected, regardless of v-Abl activity.  Since high levels of ARF have 
been found in tumors with mutated p53, the regulation of p53 by ARF may 
be lost in 3-4-1 cells.  It is possible that the p53 protein in 3-4-1 cells has 
acquired an inactivating mutation or is expressed at low levels, which 
would prevent cell cycle arrest by ARF over-expression.  A loss of or 
mutation in the p53 protein could be one of the ways that 3-4-1 cells 
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survive such high levels of ARF.  Activated-p53 protein levels were 
investigated and discussion is below.      
 P21 accumulation in the cytoplasm is known to lead to cell cycle 
arrest (modulated by p53) and has recently been shown to positively 
regulate autophagy in nutrient-rich conditions, possibly through AMPK-
mediated modulation of HDAC (histone deacetylase) activity which is 
crucial in controlling p21 expression78.  Given that p21 can cause cell 
cycle arrest, we expected to see increased levels of this protein in S9 cells 
upon v-Abl inactivation and re-activation, which would correlate with the 
cell cycle data seen in Panel A.  However, S9 showed little to no 
expression of p21 regardless of v-Abl activity which is contradictory to the 
cell cycle arrest data seen in Panel A.  The lack of p21 in S9 cells could be 
a result of rapid p21 degradation given that previous work by our group 
showed that treating S9 cells with a proteasome inhibitor restored p21 
protein levels.   
 3-4-1 cells had an upregulation of p21 upon v-Abl inactivation, 
which does not correlate with the limited cell cycle arrest upon this same 
experimental condition (seen in Panel A).  Although, given that 
phosphorylated p53 is necessary for the production of p21, the presence 
of p21 in 3-4-1 cells is not expected at all because of the lack of activated 
p53 in this cell line.  The presence of p21 in 3-4-1 is contradictory to the 
cell cycle analyses and expression of other proteins.    
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 However, there are a few possible explanations for the 
contradictory p21 expression seen in 3-4-1.  First, it is possible that the 
degradation pathway, which may be the cause for reduction of p21 in S9 
(mentioned above), may be defective in 3-4-1, allowing an accumulation of 
p21.  This potential defect in protein degradation might also be linked to 
the increased/defective autophagy pathway also observed in this tumor 
line.  Conversely, Xia et al (2011) recently explained that p21 is not 
necessary for cell cycle arrest in some cell lines and, additionally, may 
play antiapoptotic roles.  It is possible that the 3-4-1 cell line may have an 
augmented p21/cell cycle arrest/apoptosis relationship as well.           
 One explanation for the difference in p21 seen between S9 and 3-
4-1 cells could be related to the higher levels of autophagy in 3-4-1 cells.  
As previously mentioned, p21 can positively feed into the autophagy 
pathway78.  It is possible that 3-4-1 cells have a much higher level of p21 
because of its potential utilization in autophagy in this tumor line.  
However, we can only speculate as to the cause of this seeming 
contradiction of p21 expression levels between the non-malignant and 
malignant tumor lines and realize that further investigation is needed to 
clarify this anomaly.  
 As mentioned earlier, cytoplasmic p53 has been shown to inhibit 
autophagy by a mechanism which still remains to be understood.  
However, p53 must be phosphorylated in order for it to translocate from 
the nucleus to the cytoplasm58-65.  As previously mentioned, activated p53 
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can either enhance autophagy and cell cycle arrest, or inhibit autophagy 
as described by Tasmedir et al.  The determinants which direct tumor cells 
to use either a p53-enhanced or p53-inhibited autophagy pathway is still 
not clear.  It is also important to be reminded that that ARF expression can 
activate p53 (if p53 is normal, not mutated) upon oncogenic stress, 
leading to cell cycle arrest and apoptosis.   
 While S9 shows increased activation of p53 upon v-Abl inactivation 
and reactivation, 3-4-1 had no detectable levels of P-p53, regardless of v-
Abl activity.  The high levels of P-p53 in 3-4-1 cells are contradictory to the 
high level of ARF expression (since ARF can activate p53). This suggests 
that 3-4-1 cells have adapted the p53-independent autophagy pathway in 
which autophagy is induced in a manner that is independent of the PI3K-
IA/AMPK/AKT/mTOR pathways (see Figure 5) and the presence of p53 
actually inhibits the induction of autophagy.  If this is the case, the lack of 
activated p53 in 3-4-1 cells could further explain the enhanced autophagy 
pathway witnessed in this tumor line.   
 Modulation of v-Abl activity had no effect on the expression of total 
and phosphorylated AKT (data not shown).  The unaltered expression and 
activation of AKT correlates with the possibility that 3-4-1 may have 
adopted the p53-independent autophagy pathway.  As previously 
mentioned, AKT can be phosphorylated and activated by PI3K class-I 
activity, leading to the inhibition the AMPK pathway and, eventually, 
positive regulation of autophagy (see Figure 6).  If these cells utilized the 
  35 
p53-dependent autophagy pathway, AKT activation would be increased in 
correlation with an increase in autophagy.  However, both S9 and 3-4-1 
cells have consistent expression and activation levels of AKT.  
Additionally, according to the previously discussed western blot data, 3-4-
1 cells do show signs of upregulated autophagy and a lack of activated 
p53.  Taken together, this data suggests that 3-4-1 cells have adopted the 
p53-independent autophagy pathway (see Figure 5).           
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Panels B and C: Immunoblots of autophagy-related proteins in S9 and 3-
4-1 cell lines in response to basally active v-Abl (+), inactivated v-Abl (-), 
reactivated v-Abl (++), and 40 ng/ml Doxorubicin (DOX).     
 
3-4-1 is sensitive to AMPK and PI3K inhibition (Panel D) 
 As previously mentioned the AMPK and PI3K pathways can 
modulate autophagic induction and processing (see Figure 6).  It was also 
been suggested by many groups (explained above) that tumor cells often 
have an upregulated autophagy pathway which might be a route of 
survival in the presence of oncogenic stress or chemotherapies.  To 
determine the involvement of these pathways in S9 and 3-4-1, we 
evaluated the cell cycle responses to inhibition of the AMPK and PI3K.  
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Given that 3-4-1 cells have an enhanced autophagy pathway, which 
seems independent of v-Abl activation status, we suspect S9 and 3-4-1 
cells to exhibit different responses to AMPK and PI3K inhibition.   
 For the following experiment, we treated S9 and 3-4-1 cells for 24 
hours with 0.1% DMSO (dimethyl sulfoxide, the drug carrier), 10 uM of 
Compound C (an AMPK-inhibitor) in 0.1% DMSO, or 10 uM of LY294002 
(a PAN-PI3K-inhibitor) in 0.1% DMSO.  The treated cells were then 
analyzed for cell cycle (as previously described) and  the AMPK-inhibitor-
treated cells were also analyzed for apoptosis through staining with 
FITC(fluorescein isothiocyanate)-conjugated Annexin-V protein and PI, 
followed by flow cytometric analysis.  
 Cell Cycle.  Inhibition of AMPK caused G1 and G2 arrest (peaks in 
M2 and M4 regions, respectively) in both S9 and 3-4-1.  However, the G1 
arrest in 3-4-1 cells was coupled with massive apoptosis as indicated by 
the peak in the M1 region.  This apoptotic population was not seen in S9 
cell, suggesting that 3-4-1 have an enhanced sensitivity to AMPK-
inhibition.  These results are similar to the cell cycle reaction to treatment 
with the PI3K inhibitor (apoptosis and G1 arrest).  This suggests that 3-4-1 
also have an enhanced sensitivity to PI3K-inhibition.   
  Apoptosis (Annexin V + PI).  Annexin V protein had been shown to 
bind specifically to phosphatidylserine, which has been shown to be 
expressed on the surface of early apoptotic cells, although its cellular 
function is not yet known79,80.   By conjugating this protein to FITC, its 
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presence on the cell membrane can be assayed using flow cytometry on 
the FL1 channel.  In panel D, cells that stain positive for Annexin-V binding 
will present in the top-right and bottom-right quadrants.  
 Since the cells are not permeabilized prior to staining with Annexin-
V or PI, the PI will only be able to stain the DNA in cells that have a 
porated cell membrane which allows the entrance of PI into the cell.  
Disrupted cell membranes are a sign of later stages of apoptosis and 
necrosis.  Since the fluorescence of PI is analyzed on the FL2 channel of 
the flow cytometer, the cells that stain positive for PI (which is positive for 
cell membrane disruption and, therefore, later apoptosis/necrosis) will 
display in the top-left and top-right quadrants.   
 More simply put, the bottom-left quadrant represents healthy cells 
which will be unstained by both dyes.  The bottom-right quadrant 
represents early apoptotic cells, which have an in-tact cell membrane but 
express phosphatidylserine on the cell surface.  The top-right quadrant 
represents late apoptotic cells, which have been double-stained by both 
dyes, meaning that these cells have progressed beyond expression of 
phosphatidylserine on the cell surface to membrane disruption (complete 
apoptosis).  Finally, the top-left panel represents dead or necrotic cells, 
which have been stained by PI only, meaning that they have foregone the 
expression of phosphatidylserine on the cell surface and continued directly 
to membrane disruption.   
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 S9 cells showed some enhanced apoptosis when treated with the 
AMPK inhibitor.  More specifically, early apoptosis was increased by about 
8% and late apoptosis was enhanced by about 30%.  However, 
Compound C-mediated-apoptosis in 3-4-1 cells extremely enhanced.  
Early apoptosis was increased by about 23% and late apoptosis was 
increased by about 47%.  This data strengthens the previously mentioned 
cell cycle findings that 3-4-1 cells have an enhanced sensitivity to AMPK-
inhibition.  
 Recall the previous explanation of AMPK and its positive 
modulation of the autophagy pathway.  One explanation for the massive 
apoptosis seen in 3-4-1 cells following AMPK-inhibition could be that these 
cells are, somehow, reliant on the autophagy pathway to the point that 
inhibition of autophagy results in massive death.  This finding coincides 
with the previous groups that found the autophagy pathway up-regulated 
in tumor cells when treated with radiation or medicinal therapies64-69.  The 
notable finding in this study is that 3-4-1 shows signs of enhanced 
autophagy at all times, even when no perturbations are inflicted.  This may 
indicate that 3-4-1 tumor cells rely on autophagy for survival in general or, 
in other words, these cells are addicted to the autophagy pathway.   
 Vucicevic, L.  et al.  (2009) recently found that induction of 
apoptosis through treatment with Compound C can occur in a mechanism 
independent of the AMPK pathway itself.  They found that Compound C 
can elevate cellular accumulation of ROS to the point of causing cell death 
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via oxidative stress.  Given that 3-4-1appears to have an intrinsic higher 
level of ROS (Panel A), their sensitivity to compound C may be due to an 
excessive amount of ROS generated inside the cells to cause demise of 
the cells. To test this hypothesis, we used an antioxidant scavenger to see 
if it could rescue these cells from the massive apoptosis upon treatment 
with Compound C.   
 To investigate the presence of this phenomenon in 3-4-1 cells, we 
also tried a co-treatment of 10 uM Compound C and 3 mM N-
acetylcysteine (NAC) for 24 hours in S9 and 3-4-1 cells.  The addition of 
the antioxidant did not rescue the 3-4-1 cells from Compound C-induced 
apoptosis, nor did it reduce the accumulation of cellular ROS (data not 
shown).  This finding indicates that the apoptosis induced in 3-4-1 cells, 
when treated with Compound C, is related to AMPK-inhibition and not due 
to an accumulation of cellular ROS.  Given the necessity of AMPK to the 
autophagy pathway, the possible addiction of 3-4-1 cells to the autophagy 
pathway seems more plausible in that inhibition of autophagy by AMPK-
inhibition kills these tumor cells.         
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Panel D: 3-4-1 is sensitive to AMPK and PI3K inhibition.  Rows 1 and 3 
indicate the cell cycle analyses of S9 and 3-4-1 cells, respectively, treated 
with 0.1% drug carrier (DMSO), 10 uM Compound C (AMPK-inhibitor, or 
10 uM LY294002 (PI3K-inhibitor) for 24 hours.  The DMSO and 
Compound-C treated samples were further analyzed for apoptosis via 
Annexin-V and PI double-staining (S9 in row 2 and 3-4-1 in row 4).  
 
Autophagy Inhibition Leads to Massive Apoptosis in 3-4-1 (Panel E) 
 Taking all of the data explained above into consideration, it is 
apparent that 3-4-1 cells are somehow addicted to autophagy for survival.  
If this is the case, the mere inhibition of autophagy itself should yield a 
S9
DMSO 10 uM AMPK‐inh. 10 uM PI3K‐inh.
3‐
4‐
1
Ce
ll 
Cy
cl
e
Ce
ll 
Cy
cl
e
D
A
nn
ex
in
 V
 
+ 
PI
A
nn
ex
in
 V
 
+ 
PI FL
2
FL
2
FL
2
FL
2
  42 
fatal blow to the 3-4-1 tumor line.  To explore this possibility, we used an 
autophagy-inhibiting drug known as Bafilomycin A1.  Bafilomycin A1 is an 
antibiotic that is a specific inhibitor of vacuolar-type H+-ATPase82.  This 
drug inhibits autophagy by prevention the acidification of lysosomes and 
preventing lysosomal fusion with autophagosomes83.  Cell cycle was 
analyzed in S9 and 3-4-1 cells in which v-Abl was active, inactivated, and 
reactivated (as in Panel A) with and without treatment with 50 nM of 
Bafilomycin A1.   
 S9 cells show some sensitivity to Bafilomycin A1 when v-Abl is 
reactivated as indicated by the apoptotic population in region M1 of the 
cell cycle analysis.  However, 3-4-1 cells show that Bafilomycin A1 
induces apoptosis even when v-Abl is normally activated.  The percentage 
of apoptotic 3-4-1 cells is exacerbated when v-Abl is inactivated in the 
presence of Bafilomycin A1.  Furthermore, v-Abl reactivation in the 
presence of Bafilomycin A1 leads to total annihilation of 3-4-1 cells.  This 
data suggests that 3-4-1 cells somewhat rely on the autophagy pathway to 
survive v-Abl inactivation and reactivation.  More importantly, 3-4-1 cells 
might require autophagy to maintain survival or Imatinib-resistance. 
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Panel E: Autophagy inhibition leads to massive apoptosis in 3-4-1.  Cell 
cycle analysis of S9 (rows 1 and 2) and 3-4-1 (rows 3 and 4) cells while v-
Abl is active (column 1), inactive (column 2)  and reactivated (column 3) in 
the absence (DMSO: rows 1 and 3) and presence of 50 nM Bafilomycin 
A1 (rows 2 and 4). 
 
Analysis of Apoptosis Pathway (Panel F) 
 We evaluated the apoptosis-related-proteins present in S9 and 3-4-
1 as a means of determining the potentially cytocidal effects of v-Abl 
inactivation and reactivation.   
 Immunoblotting and antibodies specific to apoptosis-associated 
proteins (PARP, caspase-3, and XIAP) revealed the apoptotic profiles of 
S9 and 3-4-1 when v-Abl is active (+), Inactive (-), reactive (++), and in the 
presence of 40 ng/ml of Doxorubicin (apoptosis control).  PARP 
[poly(ADP-ribose) polymerase] is a protein involved with programmed cell 
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death stimulated by metabolic-, chemical-, or radiation-induced damage.  
PARP has been shown to be cleaved by activated caspase-3 upon the 
induction of apoptosis84.  Caspase-3 is a member of the caspase family of 
enzymes that, upon activation, initiate a cascade of cleavage events which 
lead to apoptotic cell death.  This cascade originated at the cell 
membrane, where caspase-8 is activated by death receptors, which is 
followed by the cleavage (activation) of other caspases terminating at 
caspase-3 cleavage which directly leads to apoptosis85.   Although 
caspase-3 activation was previously thought to stimulate apoptosis in an 
irreversible manner, XIAP (X-linked inhibitor-of-apoptosis protein) has 
recently been shown to directly inhibit caspase-3 and be down regulated 
by the activation of caspase-386. 
 S9 shows no signs of apoptosis induction regardless of v-Abl 
activity.  However, 3-4-1 shows apoptosis at all levels of v-Abl activity, 
even in the control cells (as indicated by PARP cleavage).  The reduction 
in XIAP correlates with the increase in caspase-3 activation as activated 
caspase-3 inhibits XIAP expression.  This apoptosis in 3-4-1 is 
contradictory to the results in Panel A which indicate that 3-4-1 has more 
active cell cycle and doubling than S9 when v-Abl is inactivated and 
reactivated. 
 As previously mentioned, v-Abl transformation begins with primary 
transformation (characterized by proliferation), followed by crisis (indicated 
by erratic cell growth and massive apoptosis), resulting in the surviving 
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cells becoming fully transformed.  One possibility is that the signs of 
apoptosis seen in 3-4-1 cells could be remnants of the crisis phase of v-
Abl transformation.  More specifically, 3-4-1 may have escaped complete 
eradication during the crisis phase of v-Abl transformation by adopting a 
high level of autophagy as a means of survival or, in other words, an up-
regulated autophagy pathway may have help these cells to remain in the 
crisis phase of transformation indefinitely.  This theory of 3-4-1 autophagy-
addiction/dependence accounts for the massive apoptosis induced when 
components of the autophagy pathway (AMPK, PI3K and lysosomal 
acidification) are inhibited.  Furthermore, the high levels of apoptosis in 3-
4-1, observed by western blot (Panel F) supports the possibility that 3-4-1 
are, indeed, in some form of crisis independent of v-Abl activity.            
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Panel F: 3-4-1 shows signs of apoptosis.  Lysates from S9 and 3-4-1 cells 
when v-Abl is basally active (+), inactive (-), reactivated (++), and treated 
with 40 ng/ml for 24 hours (DOX) were subjected to immunoblot and 
probed for PARP, caspase-3 and XIAP proteins.    
 This finding suggests that although 3-4-1 can escape v-abl 
inactivation, there is still a fraction of cells are susceptible to apoptosis. 
So, whatever mutation allows the cells to bypass the cell cycle arrest 
imposed by v-abl inactivation may also make some cells vulnerable to cell 
death. Yet, the death of these cells had little consequence on the whole 
population as a substantial number of cells continue grow despite some 
casualty. Thus, 3-4-1- cells are continuously undergoing selection for 
survival, in which some succeed and become more malignant whereas 
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others could be selected out because of acquired mutation may not be 
permissive for survival. 
 
3-4-1 has an accumulation of ROS and abnormal mitochondria (Panel 
G) 
 ROS accumulation.  Levels of total ROS (reactive oxygen species 
in the form of H2O2) was measured with the fluorescent dye DCFDA 
(dichlorofluorescein diacetate) which directly binds to ROS in the cell 
cytoplasm, then analyzed using flow cytometry.  The fluorescent intensity 
of the resulting peak on the histogram will shift to the right with 
accumulation of ROS.  The purple peaks are the ROS in cells in which v-
Abl has been inactivated and reactivated.  The green overlay placed atop 
the purple peaks is the ROS of the control cells for comparison.  An 
accumulation of ROS can be correlated with metabolic activity (as a 
product of oxidative phosphorylation) or oxidative stress.    
 S9 cells show a decreased ROS accumulation when v-Abl is 
inactivated, and remains decreased even when v-Abl is reactivated.  This 
could be indicative of lower metabolic activity or oxidative stress.  3-4-1 
cells show an elevated level of ROS when v-Abl is inactivated, then 
remains still slightly elevated upon v-Abl reactivation.  This could be 
interpreted as an increase in metabolic activity or oxidative stress.  These 
results correlate with the doubling and cell cycle results (Panel A), which 
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all point to 3-4-1’s ability to overcome terminal cell cycle arrest upon v-Abl 
inactivation, which is synonymous to Imatinib-resistance. 
 TEM.  S9 and 3-4-1 cells were held at the v-Abl-inactivating 
temperature for 48 hours, then returned to the v-Abl-permissible 
temperature for 72 hours, then analyzed via TEM (transmission electron 
microscopy) to assess any potential structural difference between these 
two cell lines as a result of v-Abl reactivation.  Since 3-4-1 is a model for 
Imatinib-resistance, this data may uncover any structural differences 
between Imatinib-sensitive and-resistant cells.   
 The majority of cancer cells have been shown to have an 
accumulation of mitochondria which possess pleomorphisms such as 
distorted cristae and swollen matrix87 when analyzed via electron 
microscopy.  Furthermore, Xu et al.  (2005) have examined the 
mitochondria in human leukemia cells, have observed these same 
pleomorphisms, and described that these structural characteristics caused 
these cancer cells to be inadequate in mitochondrial respiration and more 
reliant on glucose uptake88. 
 The electron micrographs shown in panel G display that 3-4-1 cells 
also possess mitochondrial abnormalities such as swelling, disorganized 
cristae, and increased electron density (visible by the increased contrast in 
the image).  The mitochondria in S9 appear to be smaller and fully-
enclosed by the mitochondrial membrane, with a more regular 
organization of cristae.  This finding further strengthens the claim that the 
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3-4-1 cell line has tumorigenic qualities and might explain some of the 
autophagic tendencies of this cell line.  Furthermore, the accumulation of 
ROS in 3-4-1 upon the inactivation and re-activation of v-Abl may be a 
result of the abnormal mitochondria seen in the TEM image.  However, it 
is not clear whether the ROS accumulation in 3-4-1 is a result of the 
abnormal mitochondria or vice versa.    
 
 
Panel G: 3-4-1 has an accumulation of ROS and abnormal mitochondria.  
S9 and 3-4-1 cells were subjected to ROS assay (via DCFDA staining) 
upon v-Abl inactivation and re-activation.  Green overlay is the ROS 
accumulation in control cells with basally-active v-Abl.   TEM image from 
S9 and 3-4-1 cells that were held at the v-Abl-inactivating temperature for 
Green overlay 
= Control
G S9 3‐4‐1
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Re‐active V‐Abl
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48 hours, then returned to the v-Abl permissive temperature for 72 hours.  
Arrows indicate mitochondria. 
 
Discussion 
 As previously mentioned, both S9 and 3-4-1 cells were derived 
from pre-B cells that were harvested from SCID mice and transduced with 
ts-Ab-MuLV.  After v-Abl-activity perturbation, the 3-4-1 line diverged from 
the S9 line with its ability to re-enter the cell cycle, mimicking Imatinib-
resistance.  The Imatinib-resistance status of 3-4-1 was further verified by 
inactivating and reactivating v-Abl, and showing 3-4-1’s ability to re-enter 
the cell cycle, double, and accumulate ROS (Panel A).  Given this data, 
we can be reassured that the 3-4-1 cell line is a model for Imatinib-
resistant-Ph+ B-ALL.     
 We have shown that these Imatinib-resistant 3-4-1 cells express 
high levels of autophagy-related proteins (Panel B: LC3-I and –II, p19ARF, 
p21, ), low levels of autophagy-inhibiting (Panel C: phosphorylated-p53), 
are sensitive to the inhibition of enzymes that are crucial to the regulation 
of autophagy (Panel D) and are sensitive to direct inhibition of autophagy 
(Panel E).  Additionally, contradicting expression levels of p21 and ATG4 
must be noted.  3-4-1 was expected to have little to no expression of p21 
given the lack of activated p53 detected.  Furthermore, p21 is an enforcer 
of cell cycle arrest and, since 3-4-1 is unable to properly arrest upon v-Abl 
inactivation, we did not anticipate the p21 expression seen in 3-4-1 cells 
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(Panel C).  Additionally, since 3-4-1 seems to possess an enhanced 
autophagy level (as indicated by the elevated levels of LC3-I and –II), we 
expected these cells to also express elevated levels of ATG4 as this 
protein is essential for the completion of autophagy and recycling of LC3-II 
back to –I.   
 Given these findings alone, it is reasonable to wonder if the ability 
of 3-4-1 to resist Imatinib treatment is somehow related to an over-active 
or impaired autophagy pathway.  We were questioning whether 3-4-1 
used autophagy as a means of producing metabolic substrates when 
faced with Imatinib-induced starvation.   
 However, the findings in Panel F contradicted this previous 
hypothesis in that, although 3-4-1 cells show signs of proliferation and cell 
cycle progression, they also show signs of apoptosis.  We began to 
wonder how cells can proliferate and die at the same time.  Furthermore, 
microscopic examination of 3-4-1 cells revealed no difference in viability 
than S9 cells.  In fact, 3-4-1 cells consistently grow to confluency more 
rapidly than S9. 
 Various groups that also investigate Ph+ B-ALL89-92, have turned 
their attention to ARF expression.  Mullighan et al (2008) have found that 
50-80% of all human Ph+B-ALL have deletions in ARF.  Furthermore, 
Williams et al (2008) report that B-cell progenitors respond to the 
oncogenic stress of BCR-Abl transduction by expressing ARF.  As a tumor 
suppressor, ARF expression leads to apoptosis when induced by 
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oncogenic stress unless the locus harbors an inactivating deletion or 
mutation.    
 Interestingly, Signer et al (2008) showed that all B-cell progenitors 
up to, but not including, pre-B cells do not express ARF at all.  He and his 
group later go on to show (2010) that the ability of a Ph+ B-cell progenitor 
to develop into the disease-state of leukemia is dependent upon ARF 
expression.   BCR-Abl transduction in the early B-cell progenitors HSC 
(hematopoietic stem cells), CLP (common lymphoid progenitors), and pro-
B cells (progenitor B cells) does lead to expression of ARF, but at low 
enough levels that a subset of the transduced cells survive the tumor 
suppression abilities of ARF and continue on to initiate disease.   
 Contrastingly, they also note that pre-B cells did not initiate disease 
after BCR-Abl transduction because it lead to an over-expression of ARF 
and, therefore, massive apoptosis.  They go on to stake the claim that the 
ability of the B cell lineage to initiate Ph+ B-ALL is developmentally 
regulated, disproving the previous belief that inactivation of ARF was a 
prerequisite for oncogenic-Abl transformation.  It is important to note here 
that these groups did not investigate Imatinib-resistance in their studies.   
 Parallel to Signer’s findings, the S9 cells that our group previously 
transduced with v-Abl via ts-Ab-MuLV did not reach a malignant disease 
state and, furthermore, have little to no expression of ARF and smARF 
until v-Abl reactivation (see Panel C).  This can coincide with the fact that 
S9 maintains cell cycle arrest indefinitely after v-Abl reactivation, 
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eventually leading to apoptosis.  In contrast to the findings of these other 
groups, S9 cells are an established tumor line, that is non malignant, 
which was transformed with v-Abl while these other groups studies 
primary pro- and pre-B cells transduced with BCR-Abl.  Upon 
transformation, S9 cells did increase their expression of ARF initially as a 
response to the oncogenic stress of v-Abl.  Then, to establish itself as 
tumor, the transformed S9 population probably underwent a selection for 
low levels of ARF expression as a means of survival.   
 Also, in parallel with William’s, Mullighan’s and Signer’s findings, 3-
4-1 cells do have an enhanced expression of ARF at all levels of v-Abl 
activity given that they are constantly suffering from the oncogenic stress 
of expressing the BCR-Abl gene.  The elevated ARF expression on 3-4-1 
may also account for the expression of apoptosis-related proteins seen in 
Panel F.   
 Although 3-4-1 cells do express higher levels of ARF and show 
signs of apoptosis, this cell line also managed to progress to the malignant 
disease state (by forming tumors in vivo) and beyond by acquiring 
Imatinib-resistance (as previously mentioned).  Additionally, this cell line is 
of pre-B cell lineage and has enhanced proliferative and cell cycle re-entry 
abilities when v-Abl is reactivated (see Panel A).  These phenomena are 
contradictory to Signer’s findings.  Somehow, 3-4-1 has high levels of 
active ARF but is still able to proliferate and cause disease.  An 
explanation for this might be that 3-4-1 cells express elevated ARF as a 
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sign of oncogenic stress, but are able to survive as a result of an 
inactivating/deleting p53 mutation.  This would also account for the high 
levels of apoptosis-related proteins seen in this cell line.  Accordingly, it 
can be speculated that the inactivation of ARF in 3-4-1 cells would further 
enhance its tumorigenic potential. 
 Given that the 3-4-1 cell line is an apparent anomaly, we wonder 
what is responsible for this malignant line to exist.  Two factors that were 
not accounted for in the previously-mentioned studies were examined 
here: Imatinib-resistance and enhanced autophagy.    It is possible that 
the v-Abl-perturbation leading to the creation of 3-4-1 is responsible for 
this cell line’s adoption of and seemingly addiction to autophagy as a 
means of survival in the presence of Imatinib and, luckily, also in the 
presence of ARF over-expression.   
 Recall that activated-p53 have potentially dual roles in autophagy.  
Another possibility is that 3-4-1’s lack of activated-p53 expression (see 
Panel B) could mean that this cell line adopted the alternate p53-
autophagy pathway as described by Tasmedir et al in which 
activated/cytoplasmic-p53 acts as an inhibitor of autophagy and not an 
inducer (see Figure 6).  The decision to adopt this pathway could be a 
result of forced Imatinib-resistance, autophagy, or, perhaps, enhanced 
expression of ARF.   
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Figure 7.  3-4-1 may utilize the alternate p53-signaling pathway to favor 
autophagy-progression. 
 All in all, we are potentially faced with a question of causality.  
Given that S9 and 3-4-1 cells are both established tumor lines, but only 3-
4-1 is malignant and Imatinib-resistant, leads us to believe that the 
acquisition of malignancy and Imatinib-resistance may be the results of 
the same initial cause (i.e. a mutation).  It is possible that the perturbations 
of 3-4-1 to acquire Imatinib-resistance forced for the selection of cells that 
harbored an inactivating or deleting p53 mutation.  Following this potential 
mutation, 3-4-1 cells were able to survive and proliferate regardless of the 
oncogenic stress of v-Abl activity/inactivation/re-activation and the high 
levels of expressed ARF.     
 The combination of contradictory phenomena in the 3-4-1 cell line 
can serve as a useful tool for further understanding of Imatinib-resistant 
Ph+ B-ALL.  However, the series of events that occur for this cell line to 
acquire its various survival tactics remains to be understood.  More 
specifically, it would be of great importance to decipher if any one of these 
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3 characteristics is the key to this cell’s malignancy as a potential target 
for future therapies.  
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